Proteomic identification and functional validation of activins and bone morphogenetic protein 11 as candidate novel muscle mass regulators

Molecular Endocrinology

Volumn 22, Issue 12, 2008, Pages 2689-2702

  Souza, Tatyana A ^a   Chen, Xuan ^a   Guo, Yongjing ^a   Sava, Parid ^a   Zhang, Jimin ^a   Hill, Jennifer J ^b   Yaworsky, Paul J ^a   Qiu, Yongchang ^a,c  

^a PFIZER INC   (United States)

^b NATIONAL RESEARCH COUNCIL CANADA   (Canada)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVIN; ACTIVIN A; ACTIVIN RECEPTOR 2; BONE MORPHOGENETIC PROTEIN; BONE MORPHOGENETIC PROTEIN 10; BONE MORPHOGENETIC PROTEIN 11; BONE MORPHOGENETIC PROTEIN 9; LIGAND; MYELOPID; MYOSTATIN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ARTICLE; BINDING ASSAY; CELL DIFFERENTIATION; CRYSTALLIZATION; HUMAN; IN VITRO STUDY; KNOCKOUT MOUSE; MASS SPECTROMETRY; MUSCLE GROWTH; MUSCLE MASS; MYOBLAST; MYOTUBE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN PURIFICATION; PROTEOMICS; REPORTER GENE; SERUM; SIGNAL TRANSDUCTION; SYSTEMIC CIRCULATION;

ACTIVIN RECEPTORS, TYPE II; ACTIVINS; ANIMALS; BONE MORPHOGENETIC PROTEINS; CELLS, CULTURED; GROWTH DIFFERENTIATION FACTORS; HUMANS; IMMUNOGLOBULIN FC FRAGMENTS; MICE; MICE, INBRED BALB C; MUSCLE DEVELOPMENT; MUSCLES; ORGAN SIZE; PROTEIN BINDING; PROTEOMICS; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA;

BOS; CANIS FAMILIARIS; MUS;

EID: 56749170664     PISSN: 08888809     EISSN: None     Source Type: Journal    
DOI: 10.1210/me.2008-0290     Document Type: Article

References (62)

1. McPherron AC, Lawler AM, Lee SJ 1997 Regulation of skeletal muscle mass in mice by a new TGF-β superfamily member. Nature 387:83-90
2. McPherron AC, Lee SJ 1997 Double muscling in cattle due to mutations in the myostatin gene. Proc Natl Acad Sci USA 94:12457-12461
3. Schuelke M, Wagner KR, Stolz LE, Hubner C, Riebel T, Komen W, Braun T, Tobin JF, Lee SJ 2004 Myostatin mutation associated with gross muscle hypertrophy in a child. N Engl J Med 350:2682-2688
4. Mosher DS, Quignon P, Bustamante CD, Sutter NB, Mellersh CS, Parker HG, Ostrander EA 2007 A mutation in the myostatin gene increases muscle mass and enhances racing performance in heterozygote dogs. PLoS Genet 3:e79
5. Shelton GD, Engvall E 2007 Gross muscle hypertrophy in whippet dogs is caused by a mutation in the myostatin gene. Neuromuscul Disord 17:721-722
6. Zimmers TA, Davies MV, Koniaris LG, Haynes P, Esquela AF, Tomkinson KN, McPherron AC, Wolfman NM, Lee SJ 2002 Induction of cachexia in mice by systemically administered myostatin. Science 296:1486-1488
7. McCroskery S, Thomas M, Platt L, Hennebry A, Nishimura T, McLeay L, Sharma M, Kambadur R 2005 Improved muscle healing through enhanced regeneration and reduced fibrosis in myostatin-null mice. J Cell Sci 118:3531-3541
8. Bogdanovich S, Krag TO, Barton ER, Morris LD, Whittemore LA, Ahima RS, Khurana TS 2002 Functional improvement of dystrophic muscle by myostatin blockade. Nature 420:418-421
9. Bogdanovich S, McNally EM, Khurana TS 2008 Myostatin blockade improves function but not histopathology in a murine model of limb-girdle muscular dystrophy 2C. Muscle Nerve 37:308-316
10. Bogdanovich S, Perkins KJ, Krag TO, Whittemore LA, Khurana TS 2005 Myostatin propeptide-mediated amelioration of dystrophic pathophysiology. FASEB J 19:543-549
11. Hill JJ, Davies MV, Pearson AA, Wang JH, Hewick RM, Wolfman NM, Qiu Y 2002 The myostatin propeptide and the follistatin-related gene are inhibitory binding proteins of myostatin in normal serum. J Biol Chem 277:40735-40741
12. Hill JJ, Qiu Y, Hewick RM, Wolfman NM 2003 Regulation of myostatin in vivo by growth and differentiation factor-associated serum protein-1: a novel protein with protease inhibitor and follistatin domains. Mol Endocrinol 17:1144-1154
13. Lee SJ, McPherron AC 2001 Regulation of myostatin activity and muscle growth. Proc Natl Acad Sci USA 98:9306-9311
14. Thies RS, Chen T, Davies MV, Tomkinson KN, Pearson AA, Shakey QA, Wolfman NM 2001 GDF-8 propeptide binds to GDF-8 and antagonizes biological activity by inhibiting GDF-8 receptor binding. Growth Factors 18:251-259
15. Whittemore LA, Song K, Li X, Aghajanian J, Davies M, Girgenrath S, Hill JJ, Jalenak M, Kelley P, Knight A, Maylor R, O'Hara D, Pearson A, Quazi A, Ryerson S, Tan XY, Tomkinson KN, Veldman GM, Widom A, Wright JF, Wudyka S, Zhao L, Wolfman NM 2003 Inhibition of myostatin in adult mice increases skeletal muscle mass and strength. Biochem Biophys Res Commun 300:965-971
16. Wolfman NM, McPherron AC, Pappano WN, Davies MV, Song K, Tomkinson KN, Wright JF, Zhao L, Sebald SM, Greenspan DS, Lee SJ 2003 Activation of latent myostatin by the BMP-1/tolloid family of metalloproteinases. Proc Natl Acad Sci USA 100:15842-15846
17. Rebbapragada A, Benchabane H, Wrana JL, Celeste AJ, Attisano L 2003 Myostatin signals through a transforming growth factor β-like signaling pathway to block adipogenesis. Mol Cell Biol 23:7230-7242
18. Lee SJ, Reed LA, Davies MV, Girgenrath S, Goad ME, Tomkinson KN, Wright JF, Barker C, Ehrmantraut G, Holmstrom J, Trowell B, Gertz B, Jiang MS, Sebald SM, Matzuk M, Li E, Liang LF, Quattlebaum E, Stotish RL, Wolfman NM 2005 Regulation of muscle growth by multiple ligands signaling through activin type II receptors. Proc Natl Acad Sci USA 102:18117-18122
19. de Caestecker M 2004 The transforming growth factor-β superfamily of receptors. Cytokine Growth Factor Rev 15:1-11
20. Pangas SA, Woodruff TK 2000 Activin signal transduction pathways. Trends Endocrinol Metab 11:309-314
21. Phillips DJ 2000 Regulation of activin's access to the cell: why is mother nature such a control freak? Bioessays 22:689-696
22. Kretzschmar M, Massague J 1998 SMADs: mediators and regulators of TGF-β signaling. Curr Opin Genet Dev 8:103-111
23. Dennler S, Itoh S, Vivien D, ten Dijke P, Huet S, Gauthier JM 1998 Direct binding of Smad3 and Smad4 to critical TGF β-inducible elements in the promoter of human plasminogen activator inhibitor-type 1 gene. EMBO J 17:3091-3100
24. Korchynskyi O, ten Dijke P 2002 Identification and functional characterization of distinct critically important bone morphogenetic protein-specific response elements in the Id1 promoter. J Biol Chem 277:4883-4891
25. Joulia D, Bernardi H, Garandel V, Rabenoelina F, Vernus B, Cabello G 2003 Mechanisms involved in the inhibition of myoblast proliferation and differentiation by myostatin. Exp Cell Res 286:263-275
26. Langley B, Thomas M, Bishop A, Sharma M, Gilmour S, Kambadur R 2002 Myostatin inhibits myoblast differentiation by down-regulating MyoD expression. J Biol Chem 277:49831-49840
27. Rios R, Carneiro I, Arce VM, Devesa J 2002 Myostatin is an inhibitor of myogenic differentiation. Am J Physiol Cell Physiol 282:C993-C999
28. Thomas M, Langley B, Berry C, Sharma M, Kirk S, Bass J, Kambadur R 2000 Myostatin, a negative regulator of muscle growth, functions by inhibiting myoblast proliferation. J Biol Chem 275:40235-40243
29. Kang Q, Sun MH, Cheng H, Peng Y, Montag AG, Deyrup AT, Jiang W, Luu HH, Luo J, Szatkowski JP, Vanichakarn P, Park JY, Li Y, Haydon RC, He TC 2004 Characterization of the distinct orthotopic bone-forming activity of 14 BMPs using recombinant adenovirus-mediated gene delivery. Gene Ther 11:1312-1320
30. Cheng H, Jiang W, Phillips FM, Haydon RC, Peng Y, Zhou L, Luu HH, An N, Breyer B, Vanichakarn P, Szatkowski JP, Park JY, He TC 2003 Osteogenic activity of the fourteen types of human bone morphogenetic proteins (BMPs). J Bone Joint Surg Am [Erratum (2004) 86-A:141] 85-A:1544-1552
31. Luu HH, Song WX, Luo X, Manning D, Luo J, Deng ZL, Sharff KA, Montag AG, Haydon RC, He TC 2007 Distinct roles of bone morphogenetic proteins in osteogenic differentiation of mesenchymal stem cells. J Orthop Res 25:665-677
32. Yamaguchi A, Katagiri T, Ikeda T, Wozney JM, Rosen V, Wang EA, Kahn AJ, Suda T, Yoshiki S 1991 Recombinant human bone morphogenetic protein-2 stimulates osteoblastic maturation and inhibits myogenic differentiation in vitro. J Cell Biol 113:681-687
33. Katagiri T, Yamaguchi A, Komaki M, Abe E, Takahashi N, Ikeda T, Rosen V, Wozney JM, Fujisawa-Sehara A, Suda T 1994 Bone morphogenetic protein-2 converts the differentiation pathway of C2C12 myoblasts into the osteoblast lineage. J Cell Biol 127:1755-1766
34. Katagiri T, Akiyama S, Namiki M, Komaki M, Yamaguchi A, Rosen V, Wozney JM, Fujisawa-Sehara A, Suda T 1997 Bone morphogenetic protein-2 inhibits terminal differentiation of myogenic cells by suppressing the transcriptional activity of MyoD and myogenin. Exp Cell Res 230:342-351
35. Hasty P, Bradley A, Morris JH, Edmondson DG, Venuti JM, Olson EN, Klein WH 1993 Muscle deficiency and neonatal death in mice with a targeted mutation in the myogenin gene. Nature 364:501-506
36. Weintraub H 1993 The MyoD family and myogenesis: redundancy, networks, and thresholds. Cell 75:1241-1244
37. Weintraub H, Davis R, Tapscott S, Thayer M, Krause M, Benezra R, Blackwell TK, Turner D, Rupp R, Hollenberg S 1991 The myoD gene family: nodal point during specification of the muscle cell lineage. Science 251:761-766
38. Megeney LA, Rudnicki MA 1995 Determination versus differentiation and the MyoD family of transcription factors. Biochem Cell Biol 73:723-732
39. Yang W, Zhang Y, Li Y, Wu Z, Zhu D, McFarlane C, Plummer E, Thomas M, Hennebry A, Ashby M, Ling N, Smith H, Sharma M, Kambadur R, Morissette MR, Cook SA, Foo S, McKoy G, Ashida N, Novikov M, Scherrer-Crosbie M, Li L, Matsui T, Brooks G, Rosenzweig A, Zhao B, Wall RJ, Yang J, Guttridge DC 2007 Myostatin induces cyclin D1 degradation to cause cell cycle arrest through a phosphatidylinositol 3-kinase/AKT/GSK-3 β pathway and is antagonized by insulin-like growth factor 1. J Biol Chem 282:3799-3808
40. Wozney JM, Rosen V, Celeste AJ, Mitsock LM, Whitters MJ, Kriz RW, Hewick RM, Wang EA 1988 Novel regulators of bone formation: molecular clones and activities. Science 242:1528-1534
41. Deng ZL, Sharff KA, Tang N, Song WX, Luo J, Luo X, Chen J, Bennett E, Reid R, Manning D, Xue A, Montag AG, Luu HH, Haydon RC, He TC 2008 Regulation of osteogenic differentiation during skeletal development. Front Biosci 13:2001-2021
42. Grainger DJ, Kemp PR, Metcalfe JC, Liu AC, Lawn RM, Williams NR, Grace AA, Schofield PM, Chauhan A 1995 The serum concentration of active transforming growth factor-β is severely depressed in advanced atherosclerosis. Nat Med 1:74-79
43. Muttukrishna S, Knight PG, Groome NP, Redman CW, Ledger WL 1997 Activin A and inhibin A as possible endocrine markers for pre-eclampsia. Lancet 349:1285-1288
44. Neuhaus H, Rosen V, Thies RS 1999 Heart specific expression of mouse BMP-10 a novel member of the TGF-β superfamily. Mech Dev 80:181-184
45. Olson EN, Sternberg E, Hu JS, Spizz G, Wilcox C 1986 Regulation of myogenic differentiation by type β transforming growth factor. J Cell Biol 103:1799-1805
46. Massague J, Cheifetz S, Endo T, Nadal-Ginard B 1986 Type β transforming growth factor is an inhibitor of myogenic differentiation. Proc Natl Acad Sci USA 83:8206-8210
47. Li Y, Foster W, Deasy BM, Chan Y, Prisk V, Tang Y, Cummins J, Huard J 2004 Transforming growth factorbeta1 induces the differentiation of myogenic cells into fibrotic cells in injured skeletal muscle: a key event in muscle fibrogenesis. Am J Pathol 164:1007-1019
48. Scharpfenecker M, van Dinther M, Liu Z, van Bezooijen RL, Zhao Q, Pukac L, Lowik CW, ten Dijke P 2007 BMP-9 signals via ALK1 and inhibits bFGF-induced endothelial cell proliferation and VEGF-stimulated angiogenesis. J Cell Sci 120:964-972
49. David L, Mallet C, Mazerbourg S, Feige JJ, Bailly S 2007 Identification of BMP9 and BMP10 as functional activators of the orphan activin receptor-like kinase 1 (ALK1) in endothelial cells. Blood 109:1953-1961
50. Kollias HD, McDermott JC 2008 Transforming growth factor-β and myostatin signaling in skeletal muscle. J Appl Physiol 104:579-587
51. Wu HH, Ivkovic S, Murray RC, Jaramillo S, Lyons KM, Johnson JE, Calof AL 2003 Autoregulation of neurogenesis by GDF11. Neuron 37:197-207
52. Ge G, Hopkins DR, Ho WB, Greenspan DS 2005 GDF11 forms a bone morphogenetic protein 1-activated latent complex that can modulate nerve growth factor-induced differentiation of PC12 cells. Mol Cell Biol 25:5846-5858
53. Gamer LW, Cox KA, Small C, Rosen V 2001 Gdf11 is a negative regulator of chondrogenesis and myogenesis in the developing chick limb. Dev Biol 229:407-420
54. He L, Vichev K, Macharia R, Huang R, Christ B, Patel K, Amthor H 2005 Activin A inhibits formation of skeletal muscle during chick development. Anat Embryol (Berl) 209:401-407
55. Link BA, Nishi R 1997 Opposing effects of activin A and follistatin on developing skeletal muscle cells. Exp Cell Res 233:350-362
56. Lee SJ 2007 Quadrupling muscle mass in mice by targeting TGF-β signaling pathways. PLoS ONE 2:e789
57. Shimonaka M, Inouye S, Shimasaki S, Ling N 1991 Follistatin binds to both activin and inhibin through the common subunit. Endocrinology 128:3313-3315
58. Krummen LA, Woodruff TK, DeGuzman G, Cox ET, Baly DL, Mann E, Garg S, Wong WL, Cossum P, Mather JP 1993 Identification and characterization of binding proteins for inhibin and activin in human serum and follicular fluids. Endocrinology 132:431-443
59. Bilezikjian LM, Blount AL, Leal AM, Donaldson CJ, Fischer WH, Vale WW 2004 Autocrine/paracrine regulation of pituitary function by activin, inhibin and follistatin. Mol Cell Endocrinol 225:29-36
60. Nomura T, Ueyama T, Ashihara E, Tateishi K, Asada S, Nakajima N, Isodono K, Takahashi T, Matsubara H, Oh H 2008 Skeletal muscle-derived progenitors capable of differentiating into cardiomyocytes proliferate through myostatin-independent TGF-β family signaling. Biochem Biophys Res Commun 365:863-869
61. Amthor H, Nicholas G, McKinnell I, Kemp CF, Sharma M, Kambadur R, Patel K 2004 Follistatin complexes myostatin and antagonises myostatin-mediated inhibition of myogenesis. Dev Biol 270:19-30
62. Shevchenko A, Wilm M, Vorm O, Mann M 1996 Mass spectrometric sequencing of proteins silver-stained polyacrylamide gels. Anal Chem 68:850-858